Stoke Therapeutics, which is developing therapies that increase gene expression to treat severe genetic diseases, filed on Thursday with the SEC to raise up to $86 million in an initial public offering.
The Bedford, MA-based company was founded in 2014 and plans to list on the Nasdaq under the symbol STOK. Stoke Therapeutics filed confidentially on March 26, 2019. J.P. Morgan, Cowen, and Credit Suisse are the joint bookrunners on the deal. No pricing terms were disclosed.
